by Paul Arnold, Medical Xpress edited by Gaby Clark, reviewed by Robert Egan Editors’ notes Identification of leanness-inducing microbes from the SF community(A and B) (A) Fasting blood glucose and (B) serum triglycerides of 8-week-old male WT and T-MyD88−/− mice on an HFD supplemented with SF for 2 months (WT, n = 10; T-Myd88−/−, n = 13). Credit: Cell Metabolism (2025). […]
Gut bacterium could be key to tackling obesity crisis Read More »
by Sanford-Burnham Prebys edited by Gaby Clark, reviewed by Robert Egan Editors’ notes DeepTarget’s predictions are based on the principle that removing a gene encoding the protein target of a given drug through CRISPR-Cas9 gene editing can mimic the inhibitory effects of that drug. The tool was built by leveraging large-scale genetic and drug screening experiments with comprehensive
Computational deep dive reveals hidden cancer drug targets and repurposing opportunities Read More »
by University of North Carolina at Chapel Hill edited by Gaby Clark, reviewed by Andrew Zinin Editors’ notes Induced periodontitis prompts severe bone destruction in male mice. Credit: Proceedings of the National Academy of Sciences (2025). DOI: 10.1073/pnas.250709212 A study out of the University of North Carolina at Chapel Hill has unveiled new insights into the inflammatory processes behind periodontitis,
Inflammasome found to drive male-specific bone loss in gum disease Read More »
edited by Andrew Zinin Editors’ notes Credit: Pixabay/CC0 Public Domain The United States on Friday said it would add its most serious warning label to a gene therapy treatment for a debilitating muscle-wasting disease, and also limit its approved use. The Food and Drug Administration said the decision to narrow the approved use of Elevidys—which is
US narrows use of muscle-wasting therapy after teen deaths Read More »
by Association for Molecular Pathology edited by Sadie Harley, reviewed by Robert Egan Editors’ notes Credit: CC0 Public Domain Scientists at Brigham and Women’s Hospital and Harvard Medical School have developed a targeted genetic test to improve diagnosis for X-linked dystonia-parkinsonism (XDP), a rare and disabling movement disorder that affects primarily men of Filipino ancestry. The work
New genetic test targets elusive cause of rare movement disorder Read More »
By Maya Goldman, Tina Reed and Peter Sullivan · Nov 15, 2025 Miss us yet? Today we’re kicking off four special Saturday editions of Vitals aimed at showcasing key health issues and how they’ll play out in the coming year. Situational awareness: Medicare administrators said yesterday that the monthly Part B premium for outpatient services will rise $17.60
A new drug currently known as NG101 reduced nausea and vomiting in patients with obesity using GLP-1s by 40% and 67%, respectively, based on data from a phase 2 trial presented at the Obesity Society’s Obesity Week 2025 in Atlanta. Previous research published in JAMA Network Open showed a nearly 65% discontinuation rate for three GLP-1s (liraglutide, semaglutide, or tirzepatide) among
New Drug Eases Side Effects of Weight-Loss Meds Read More »
Vitae, vulputate lorem id egestas neque egestas habitant sit ante nec.
✆ Phone (appointments): 714-639-4013
Email: care@imedmg.com
Address: 615 E Chapman Ave, Suite #300, Orange, CA 92866